Home Cart 0 Sign in  

[ CAS No. 331647-05-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 331647-05-3
Chemical Structure| 331647-05-3
Structure of 331647-05-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 331647-05-3 ]

Related Doc. of [ 331647-05-3 ]

Alternatived Products of [ 331647-05-3 ]

Product Details of [ 331647-05-3 ]

CAS No. :331647-05-3 MDL No. :MFCD09954891
Formula : C8H3BrCl2N2 Boiling Point : -
Linear Structure Formula :- InChI Key :BHXJPWCPEFXWMH-UHFFFAOYSA-N
M.W : 277.93 Pubchem ID :13785874
Synonyms :

Calculated chemistry of [ 331647-05-3 ]

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.0
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 0.0
Molar Refractivity : 57.26
TPSA : 25.78 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : Yes
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.05 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.52
Log Po/w (XLOGP3) : 4.15
Log Po/w (WLOGP) : 3.7
Log Po/w (MLOGP) : 2.87
Log Po/w (SILICOS-IT) : 3.86
Consensus Log Po/w : 3.42

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.75
Solubility : 0.00498 mg/ml ; 0.0000179 mol/l
Class : Moderately soluble
Log S (Ali) : -4.4
Solubility : 0.0111 mg/ml ; 0.0000399 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.41
Solubility : 0.00108 mg/ml ; 0.00000389 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.75

Safety of [ 331647-05-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 331647-05-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 331647-05-3 ]
  • Downstream synthetic route of [ 331647-05-3 ]

[ 331647-05-3 ] Synthesis Path-Upstream   1~8

  • 1
  • [ 331647-05-3 ]
  • [ 331647-04-2 ]
Reference: [1] Patent: US6399603, 2002, B1,
  • 2
  • [ 331646-99-2 ]
  • [ 331647-05-3 ]
YieldReaction ConditionsOperation in experiment
76%
Stage #1: at 110 - 120℃; Heating / reflux
Stage #2: With sodium hydrogencarbonate In dichloromethane; water
To a flask charged with 8-bromoquinazoline-2,4-diol 2 (39.61 g, 164 mmol) was added PCI5 (68.4 g, 328 mmol) and POCI3, (250 mL). The mixture was refluxed at 110-1200C overnight with a drying tube attached. POCI3 was stripped off under vacuum. Toluene was added to azeotroped the remaining POCI3. The residue was taken into DCM (300 mL), washed with sat NaHCO3 (500 mL), filtered and dried over Na2SO4. The organic layer was concentrated in vacuo and the residue was purified by chromatography to give the title compound as white solid (34.67 g, 76percent). 1HNMR (CDCI3, 400 MHz): δ 8.31 (dd, J = 1.2, 7.6 Hz, 1 H), 8.27 (dd, J = 1.2, 8.4 Hz, 1 H), 7.62 (dd, J = 7.6, 8.4 Hz, 1 H).
40% With trichlorophosphate In <i>N</i>,<i>N</i>-dimethyl-aniline at 110℃; for 18 h; Compound 19-f (5.5 g, 22.9 mmol) was dissolved in phosphorus oxychloride (30 mL), N,N-dimethylaniline (5mL) was added and the reaction mixture was heated at 110°C for 18 hours. The reaction mixture was cooled to roomtemperature, the reaction mixture was concentrated under reduced pressure to remove phosphorus oxychloride. Theresidue was concentrated and dried. The residue was dissolved with dichloromethane (500 mL) and washed with water(500 mL). The separated organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentratedunder reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: dichloromethane= 3: 1) to deliver a pale yellow solid 19-e (2.5 g, yield: 40percent). LC-MS (ESI): m/z = 277 [M+H]+.
2.5 g With trichlorophosphate In <i>N</i>,<i>N</i>-dimethyl-aniline at 110℃; for 18 h; Compound 44-f (5.5 g, 22.9 mmol) was dissolved in phosphorus oxychloride (30 mL), N,N-dimethylaniline (5 mL) was added and the reaction solution was heated at 110° C. for 18 hours. The reaction was cooled to room temperature and concentrated under reduced pressure to remove phosphorus oxychloride. The residue was concentrated to dryness and the residue was dissolved in dichloromethane (500 mL) and washed with water (500 mL). The separated organic phase was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: dichloromethane=3:1) to give 44-e as a pale yellow solid (2.5 g, yield 40percent). LC-MS (ESI): m/z=277[M+H]+.
Reference: [1] Patent: WO2007/125405, 2007, A2, . Location in patent: Page/Page column 25; 81
[2] Patent: EP3287463, 2018, A1, . Location in patent: Paragraph 0191; 0193
[3] Patent: US2018/208604, 2018, A1, . Location in patent: Paragraph 0480-0481
  • 3
  • [ 331646-99-2 ]
  • [ 331647-05-3 ]
YieldReaction ConditionsOperation in experiment
60% With trichlorophosphate In N,N-dimethyl-formamide at 130℃; for 12 h; To a mixture of 8-bromoquinazoline-2,4(lH,3H)-dione (12.1 g, 50 mmol, 1 eq.) in POCl3(130 mL) was added DMF (0.5 mL). The mixture was stirred at 130 °C for 12 h, then cooled to r.t. and concentrated. The resulting residue was dissolved in EA (100 mL) and poured into ice-water with vigorous stirring. The organic phase was separated and washed with brine, dried over anhydrous Na2S04and concentrated. The resulting residue was purified via column chromatography (PE/EA==10: 1, v/v) to afford 8-bromo-2,4- dichloroquinazoline as a yellow solid (9.1 g, 60percent yield).
60% With trichlorophosphate In N,N-dimethyl-formamide at 130℃; for 12 h; [0287] To a mixture of 8-bromoquinazoline-2,4(1H,3H)-dione (12.1 g, 50 mmol, 1 eq.) in POC13 (130 mL) was added DMF (0.5 mL). The mixture was stirred at 130 °C for 12 h, then cooled to r.t. and concentrated. The resulting residue was dissolved in EA (100 mL) and poured into ice-water with vigorous stirring. The organic phase was separated and washed with brine, dried over anhydrous Na2 SO4 and concentrated. The resulting residue was purified via column chromatography (PE/EA==10:1, v/v) to afford 8-bromo-2,4- dichloroquinazoline as a yellow solid (9.1 g, 60percent yield).
Reference: [1] Organic Letters, 2011, vol. 13, # 4, p. 676 - 679
[2] ACS Medicinal Chemistry Letters, 2018, vol. 9, # 9, p. 941 - 946
[3] Patent: WO2015/27222, 2015, A2, . Location in patent: Paragraph 0214
[4] Patent: WO2016/133935, 2016, A1, . Location in patent: Paragraph 0287
  • 4
  • [ 20776-51-6 ]
  • [ 331647-05-3 ]
Reference: [1] Patent: WO2015/27222, 2015, A2,
[2] Patent: WO2016/133935, 2016, A1,
[3] Patent: EP3287463, 2018, A1,
[4] Patent: US2018/208604, 2018, A1,
[5] ACS Medicinal Chemistry Letters, 2018, vol. 9, # 9, p. 941 - 946
  • 5
  • [ 608-30-0 ]
  • [ 331647-05-3 ]
Reference: [1] Organic Letters, 2011, vol. 13, # 4, p. 676 - 679
  • 6
  • [ 114344-60-4 ]
  • [ 331647-05-3 ]
Reference: [1] Organic Letters, 2011, vol. 13, # 4, p. 676 - 679
  • 7
  • [ 331647-05-3 ]
  • [ 956100-63-3 ]
Reference: [1] Patent: WO2015/27222, 2015, A2,
[2] Patent: EP3287463, 2018, A1,
[3] Patent: US2018/208604, 2018, A1,
  • 8
  • [ 331647-05-3 ]
  • [ 956100-62-2 ]
YieldReaction ConditionsOperation in experiment
100% With ammonia In methanol; dichloromethane at 20℃; for 16 h; Compound 19-e (1.2 g, 4.35 mmol) was dissolved in dichloromethane (5 mL) and then ammonia (50 mL, 7 Min methanol), was added and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixturewas concentrated under reduced pressure and the residue was added to water (50 mL), a solid was precipitated andfiltered. The filter cake was washed with water (50 mL) and dried in vacuo to deliver a yellow solid 19-d (1.5 g, yield:100percent). This product was used directly for the next step without further purification
99% With ammonia In dichloromethane at 20℃; 8-bromo-2,4-dichloroquinazoline (13.90 g, 50 mmol) was dissolved in DCM (60 mL) and ammonia was bubbled through the reaction solution with stirring overnight at room temperature. A suspension was formed, and the precipitate was collected by filtration to give crude title compound as a white solid (12.93 g, 99percent).
83.5% With ammonium hydroxide In tetrahydrofuran at 0℃; for 0.5 h; To a solution of ammonia hydroxide (25 mL, 330 mmol, 10 eq.) in THF (50 mL) cooled to 0 °C was added a solution of 8-bromo-2,4-dichloroquinazoline (9.1 g, 32.7 mmol, 1 eq.) in THF (50 mL). The mixture was stirred at 0 °C for 30 min, then diluted with EA (100 mL), washed with brine, dried over anhydrous Na2S04and concentrated. The resulting residue was purified via column chromatography (PE/EA=10: 1, v/v) to afford 8-bromo-2- chloroquinazolin-4-amine as a yellow solid (7.1 g, 83.5percent yield).
83.5% With ammonium hydroxide In tetrahydrofuran at 0℃; for 0.5 h; [0288] To a solution of ammonia hydroxide (25 mL, 330 mmol, 10 eq.) in THF (50 mL) cooled to 0 °C was added a solution of 8-bromo-2,4-dichloroquinazoline (9.1 g, 32.7 mmol, 1 eq.) in THF (50 mL). The mixture was stirred at 0 °C for 30 mm, then diluted with EA (100 mL), washed with brine, dried over anhydrous Na2504 and concentrated. The resulting residue was purified via column chromatography (PE/EA=10: 1, v/v) to afford 8-bromo-2- chloroquinazolin-4-amine as a yellow solid (7.1 g, 83.5percent yield).

Reference: [1] Patent: EP3287463, 2018, A1, . Location in patent: Paragraph 0191; 0194
[2] Patent: WO2007/125405, 2007, A2, . Location in patent: Page/Page column 25; 81
[3] Patent: WO2015/27222, 2015, A2, . Location in patent: Paragraph 0215
[4] Patent: WO2016/133935, 2016, A1, . Location in patent: Paragraph 0288
[5] Patent: US2018/208604, 2018, A1, . Location in patent: Paragraph 0482-0483
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 331647-05-3 ]

Bromides

Chemical Structure| 102393-82-8

[ 102393-82-8 ]

6-Bromo-2,4-dichloroquinazoline

Similarity: 0.94

Chemical Structure| 956100-63-3

[ 956100-63-3 ]

8-Bromo-2-chloroquinazoline

Similarity: 0.86

Chemical Structure| 38267-96-8

[ 38267-96-8 ]

6-Bromo-4-chloroquinazoline

Similarity: 0.85

Chemical Structure| 351426-04-5

[ 351426-04-5 ]

6-Bromo-4-chloro-2-methylquinazoline

Similarity: 0.83

Chemical Structure| 953039-66-2

[ 953039-66-2 ]

7-Bromo-2-chloroquinazoline

Similarity: 0.80

Chlorides

Chemical Structure| 102393-82-8

[ 102393-82-8 ]

6-Bromo-2,4-dichloroquinazoline

Similarity: 0.94

Chemical Structure| 956100-63-3

[ 956100-63-3 ]

8-Bromo-2-chloroquinazoline

Similarity: 0.86

Chemical Structure| 38267-96-8

[ 38267-96-8 ]

6-Bromo-4-chloroquinazoline

Similarity: 0.85

Chemical Structure| 351426-04-5

[ 351426-04-5 ]

6-Bromo-4-chloro-2-methylquinazoline

Similarity: 0.83

Chemical Structure| 39576-82-4

[ 39576-82-4 ]

2,4-Dichloro-6-methylquinazoline

Similarity: 0.82

Related Parent Nucleus of
[ 331647-05-3 ]

Quinazolines

Chemical Structure| 102393-82-8

[ 102393-82-8 ]

6-Bromo-2,4-dichloroquinazoline

Similarity: 0.94

Chemical Structure| 956100-63-3

[ 956100-63-3 ]

8-Bromo-2-chloroquinazoline

Similarity: 0.86

Chemical Structure| 38267-96-8

[ 38267-96-8 ]

6-Bromo-4-chloroquinazoline

Similarity: 0.85

Chemical Structure| 351426-04-5

[ 351426-04-5 ]

6-Bromo-4-chloro-2-methylquinazoline

Similarity: 0.83

Chemical Structure| 39576-82-4

[ 39576-82-4 ]

2,4-Dichloro-6-methylquinazoline

Similarity: 0.82